Evidence map›Paper›PMID 31698691›Full record

ArticleAntibiotics (Basel, Switzerland)2019

13-(2-Methylbenzyl) Berberine Is a More Potent Inhibitor of MexXY-Dependent Aminoglycoside Resistance than Berberine.

Kenta Kotani, Mio Matsumura, Yuji Morita, Junko Tomida, Ryo Kutsuna, Kunihiko Nishino, Shuji Yasuike, Yoshiaki Kawamura

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Regulation, structure, and activity of theAntimicrobial agents and chemotherapy · 2025
    Review
  2. Review
  3. Article
  4. Di-berberine conjugates as chemical probes ofbioRxiv : the preprint server for biology · 2023
    Article
  5. Berberine Derivatives asMolecules (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Natural Compounds as Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kenta KotaniDepartment of Microbiology, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Mio MatsumuraDepartment of Organic and Medicinal Chemistry, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Yuji MoritaDepartment of Microbial Science and Host Defense, Meiji Pharmaceutical University, Noshio, Kiyose, Tokyo 560-0043, Japan.
Junko TomidaDepartment of Microbiology, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Ryo KutsunaDepartment of Microbiology, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Kunihiko NishinoDepartment of Biomolecular Science and Regulation, Institute of Scientific and Industrial Research, Osaka University, Osaka 560-0043, Japan.
Shuji YasuikeDepartment of Organic and Medicinal Chemistry, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Yoshiaki KawamuraDepartment of Microbiology, School of Pharmacy, Aichi Gakuin University, Nagoya 560-0043, Japan.
Aichi Gakuin University · JPMeiji Pharmaceutical University · JPOsaka Research Institute of Industrial Science and Technology · JP

Funding

Japan Society for the Promotion of Science JP26460080Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan N-174102
6 · The paper itself

Abstract

We previously showed that berberine attenuates MexXY efflux-dependent aminoglycoside resistance in

Indexed as

aminoglycoside resistanceberberineeffluxMexXYPseudomonas aeruginosa

Identifiers

PMID31698691
PMCPMC6963850
OpenAlexW2411926187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.